Breaking News Instant updates and real-time market news.

2022-05-19 07:18:36 DOC Physicians Realty Trust $17.90 / -0.415 (-2.27%) , WELL Welltower $88.12 / -1.56 (-1.74%) … 07:18 05/19/22 05/19 07:18 05/19/22 07:18	Physicians Realty Trust downgraded to Underperform from Neutral at BofA BofA analyst Joshua Dennerlein downgraded Physicians Realty Trust (DOC) to Underperform from Neutral with an unchanged price target of $18. His model assumes lower growth going forward given rising interest rates, which are a headwind given that the majority of Physicians Realty's earnings growth is driven by net acquisitions. In addition, Welltower's (WELL) recent bid for Healthcare Realty Trust (HR) suggests little upside versus his net asset value estimate, Dennerlein added. DOC Physicians Realty Trust $17.90 / -0.415 (-2.27%) WELL Welltower $88.12 / -1.56 (-1.74%) HR Healthcare Realty Trust $28.04 / -0.51 (-1.79%)	23 May

2022-05-19 07:18:36

DOC

Physicians Realty Trust

$17.90 / -0.415 (-2.27%)

, WELL

Welltower

$88.12 / -1.56 (-1.74%)

… 07:18

05/19/22

05/19

07:18

05/19/22

07:18

Physicians Realty Trust downgraded to Underperform from Neutral at BofA

BofA analyst Joshua Dennerlein downgraded Physicians Realty Trust (DOC) to Underperform from Neutral with an unchanged price target of $18. His model assumes lower growth going forward given rising interest rates, which are a headwind given that the majority of Physicians Realty's earnings growth is driven by net acquisitions. In addition, Welltower's (WELL) recent bid for Healthcare Realty Trust (HR) suggests little upside versus his net asset value estimate, Dennerlein added.

DOC

Physicians Realty Trust

$17.90 / -0.415 (-2.27%)

WELL

Welltower

$88.12 / -1.56 (-1.74%)

Healthcare Realty Trust

$28.04 / -0.51 (-1.79%)

23
May

OTHER BREAKING NEWS FROM THE FLY

Downgrade	TerrAscend downgraded to Neutral from Overweight at Cantor Fitzgerald » 07:30 08/12/22 08/12 07:30 08/12/22 07:30 TRSSF TerrAscend $2.40 / +0.11 (+4.80%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 06/02/22 TerrAscend debuts Cookies, Gage brands in New Jersey 03/09/22 TerrAscend to close Gage Growth acquisition on March 10 TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 07/22/22 Seaport Global TerrAscend initiated with a Buy at Seaport Global 02/09/22 Clarus TerrAscend price target lowered to C$14 from C$16.25 at Clarus 12/08/21 Cantor Fitzgerald TerrAscend price target raised to $7.65 from $6.70 at Cantor Fitzgerald 11/17/21 Stifel TerrAscend price target lowered to C$21 from C$23 at Stifel TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 04/11/22 NJ approves sale of retail marijuana from seven dispensaries, Bloomberg says TRSSF TerrAscend $2.40 / +0.11 (+4.80%) 04/14/22 Here's What You Missed in Cannabis This Week
Downgrade	NextNav cut to Perform at Oppenheimer on capital needs » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NN NextNav $3.39 / +0.02 (+0.59%) Oppenheimer analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NN NextNav $3.39 / +0.02 (+0.59%) 08/10/22 NextNav appoints Subin as new board member 07/07/22 NextNav enters partnership with VOS Systems 06/13/22 NextNav announces The Vitals App has joined NextNav partner ecosystem 05/19/22 NextNav, Vizsafe partner for vertical location services NN NextNav $3.39 / +0.02 (+0.59%) 06:32 Today Oppenheimer NextNav downgraded to Perform from Outperform at Oppenheimer 05/16/22 R.F. Lafferty NextNav price target lowered to $15 from $16 at R.F. Lafferty 05/13/22 B. Riley NextNav price target lowered to $14.25 from $17 at B. Riley 01/06/22 R.F. Lafferty NextNav initiated with a Buy at R.F. Lafferty NN NextNav $3.39 / +0.02 (+0.59%) 08/10/22 NextNav reports Q2 revenue $1.4M vs. $216,000 last year
Recommendations	Toast price target raised to $27 from $21 at Needham » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 TOST Toast $18.12 / -0.33 (-1.79%) Needham analyst Mayank… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance 07/26/22 Cathie Wood's ARK Investment bought 113K shares of Toast today 07/07/22 Toast acquires employee scheduling, communication solution Sling, no terms 05/13/22 Toast rises 15.2% TOST Toast $18.12 / -0.33 (-1.79%) 07:17 Today KeyBanc Toast price target raised to $25 from $18 at KeyBanc 05/17/22 Mizuho Toast price target lowered to $18 from $19 at Mizuho 05/13/22 Needham Toast price target lowered to $21 from $38 at Needham 05/13/22 Canaccord Toast price target lowered to $25 from $34 at Canaccord TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 08/11/22 Toast sees Q3 revenue $700M-$730M, consensus $665.08M 08/11/22 Toast reports Q2 EPS (11c) vs (64c) last year 08/11/22 Notable companies reporting after market close 22 Sep TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Fly Intel: After-Hours Movers 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast Inc options imply 11.3% move in share price post-earnings 05/12/22 Toast Inc options imply 21.6% move in share price post-earnings 03/04/22 Toast Inc put volume heavy and directionally bearish 02/15/22 Toast Inc options imply 15.0% move in share price post-earnings
Recommendations	Nkarta price target lowered to $38 from $60 at Cantor Fitzgerald » 07:28 08/12/22 08/12 07:28 08/12/22 07:28 NKTX Nkarta $15.59 / -0.36 (-2.26%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/25/22 Nkarta promotes Ralph Brandenberger to Chief Technical Officer 04/25/22 Nkarta trading resumes 04/25/22 Nkarta trading halted, volatility trading pause 04/25/22 Nkarta announces preliminary dose finding data for two NK cell programs NKTX Nkarta $15.59 / -0.36 (-2.26%) 07/28/22 Needham Nkarta initiated with a Buy at Needham 07/18/22 SVB Securities Nkarta initiated with an Outperform at SVB Securities 04/26/22 Stifel Nkarta's AML/NHL data 'a positive' for CAR-NK space, says Stifel 04/25/22 Cantor Fitzgerald Nkarta assumed with an Overweight at Cantor Fitzgerald NKTX Nkarta $15.59 / -0.36 (-2.26%) 08/11/22 Nkarta reports Q2 EPS (61c), consensus (60c) 05/12/22 Nkarta reports Q1 EPS (79c), consensus (72c) 03/17/22 Nkarta reports Q4 EPS (69c), consensus (90c) 26 Apr NKTX Nkarta $15.59 / -0.36 (-2.26%) 04/26/22 What You Missed On Wall Street On Tuesday 04/26/22 What You Missed On Wall Street This Morning 04/25/22 Fly Intel: After-Hours Movers 04/25/22 What You Missed On Wall Street On Monday NKTX Nkarta $15.59 / -0.36 (-2.26%) 05/04/22 Nkarta call volume above normal and directionally bullish 04/25/22 Unusually active option classes on open April 25th
Initiation	Mereo BioPharma initiated with an Overweight at Cantor Fitzgerald » 07:27 08/12/22 08/12 07:27 08/12/22 07:27 MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) Cantor Fitzgerald analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 07/05/22 Mereo BioPharma regains compliance with Nasdaq minimum bid price requirement 06/02/22 Mereo announces portfolio prioritization plan, sees cash runway into late 2024 06/02/22 Mereo BioPharma to present data update for Phase 1b/2 ACTIVATE study 05/26/22 Mereo BioPharma to present updated Phase 1b/2 data on Etigilimab and Nivolumab MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/06/22 Needham Mereo BioPharma price target lowered to $5 from $10 at Needham MREO Mereo BioPharma $1.15 / -0.055 (-4.56%) 06/17/22 AstraZeneca considering bid for Mereo BioPharma, U.K. Times reports
Recommendations	Shattuck Labs price target lowered to $21 from $31 at Needham » 07:26 08/12/22 08/12 07:26 08/12/22 07:26 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) Needham analyst Chad… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs expects cash, cash equivalents to fund operations into 2H of 2024 05/12/22 Shattuck Labs sees cash, equivalents funding operations into 2H24 04/08/22 Shattuck Labs presents preclinical SL-9258 data at AACR 03/15/22 Shattuck Labs expects cash to fund operations into 2H24 STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Citi Shattuck Labs initiated with a Buy at Citi 05/02/22 H.C. Wainwright Shattuck Labs initiated with a Buy at H.C. Wainwright STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 08/11/22 Shattuck Labs reports Q2 EPS (65c), consensus (59c) 05/12/22 Shattuck Labs reports Q1 EPS (58c), consensus (50c) 03/15/22 Shattuck Labs reports Q4 EPS 18c, two est. (43c) STTK Shattuck Labs $3.68 / -0.15 (-3.92%) 06/01/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Lennar downgraded to Neutral from Outperform at Wedbush » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 LEN Lennar $87.78 / +0.47 (+0.54%) Wedbush analyst Jay… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options LEN Lennar $87.78 / +0.47 (+0.54%) 06/26/22 Fly Intel: Top five weekend stock stories 06/21/22 Housing market has cooled as expected, Lennar says 06/21/22 Lennar sees Q3 deliveries 17,000-18,500 03/17/22 Lennar raises FY gross margin view to 27.25%-28% from 27%-27.5% LEN Lennar $87.78 / +0.47 (+0.54%) 06:32 Today Wedbush Lennar downgraded to Neutral from Outperform at Wedbush 07/12/22 JPMorgan JPMorgan 'cautious and less constructive' on homebuilders, downgrades Lennar 07/12/22 JPMorgan Lennar downgraded to Neutral from Overweight at JPMorgan 06/22/22 UBS Lennar price target lowered to $106 from $108 at UBS LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 Lennar sees Q3 EPS $4.55-$5.45, consensus $4.78 06/21/22 Lennar reports Q2 EPS $4.49, consensus $3.98 03/17/22 Lennar sees Q2 EPS $3.80-$4.00, consensus $3.75 03/16/22 Lennar sees FY22 deliveries about 68,000 LEN Lennar $87.78 / +0.47 (+0.54%) 06/25/22 Lennar, Nucor among home-building and steel stocks worth a look, Barron's says 04/14/22 Mortgage rates spike to 5% amid post-pandemic price pressures, NY Times says LEN Lennar $87.78 / +0.47 (+0.54%) 06/21/22 What You Missed On Wall Street On Tuesday 06/21/22 What You Missed On Wall Street This Morning 06/21/22 Fly Intel: Pre-market Movers 03/17/22 What You Missed On Wall Street On Thursday LEN Lennar $87.78 / +0.47 (+0.54%) 07/01/22 Early notable gainers among liquid option names on July 1st 06/23/22 Early notable gainers among liquid option names on June 23rd 06/22/22 Early notable gainers among liquid option names on June 22nd 05/25/22 Early notable gainers among liquid option names on May 25th
Hot Stocks	GreenLight Bioscences announces $109M financing » 07:25 08/12/22 08/12 07:25 08/12/22 07:25 GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) GreenLight Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News GRNA GreenLight Bioscences $4.00 / +0.09 (+2.30%) 08/01/22 GreenLight, Samsung Biologics complete run for mRNA production partnership 08/01/22 GreenLight Bioscences' COVID-19 vaccine completes first engineering run 07/29/22 GreenLight Bioscences to collaborate on COVID-19 vaccine development with NIH 03/14/22 GreenLight enters into licensing agreement with Serum Institute of India
Hot Stocks	ARC Group says RM2 continues to experience 'record demand' for BLOCKPal pallets » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 ARCW ARC Group $1.00 / + (+0.00%) ARC Group Worldwide… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial
Hot Stocks	Aptinyx announces NYX-2925 study did not achieve primary endpoint » 07:22 08/12/22 08/12 07:22 08/12/22 07:22 APTX Aptinyx / + Aptinyx announced results… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options APTX Aptinyx / + 04/20/22 Aptinyx says NYX-783 data suggest potential as a treatment for PTSD 04/07/22 Aptinyx trading resumes 04/07/22 Aptinyx trading halted, news pending 04/07/22 Aptinyx announces NYX-2925 study did not achieve primary endpoint APTX Aptinyx / + 05/18/22 Piper Sandler Aptinyx price target lowered to $6 from $10 at Piper Sandler 04/14/22 H.C. Wainwright Aptinyx price target lowered to $2 from $8 at H.C. Wainwright 04/08/22 BMO Capital Aptinyx price target lowered to $6 from $12 at BMO Capital 04/08/22 Truist Aptinyx price target lowered to $5 from $12 at Truist APTX Aptinyx / + 08/04/22 Aptinyx reports Q2 EPS (26c), consensus (28c) 05/12/22 Aptinyx reports Q1 EPS (29c), consensus (30c) 03/23/22 Aptinyx reports Q4 EPS (29c), consensus (35c) APTX Aptinyx / + 03/23/22 Aptinyx options imply 6.9% move in share price post-earnings

Hot Stocks	Unity: UBX1325 injection led to clinically meaningful improvement in mean BCVA » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 UBX Unity Biotechnology / + UNITY Biotechnology… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology announces anticipated milestones 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Downgrade	Diebold downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 DBD Diebold $4.46 / -0.13 (-2.83%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Diebold rises 23.3% 05/10/22 Diebold expects to see cost savings of $150M in the next 12-18 months 03/17/22 Diebold: Shipments, sales into Russia suspended since start of Ukraine crisis DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Wedbush Wedbush upgrades Diebold, sees sales and earnings positioned to improve 07/08/22 Wedbush Diebold upgraded to Outperform from Neutral at Wedbush 05/10/22 JPMorgan Diebold downgraded to Neutral at JPMorgan after 'material' guidance cut 05/10/22 JPMorgan Diebold downgraded to Neutral from Overweight at JPMorgan DBD Diebold $4.46 / -0.13 (-2.83%) 08/02/22 Diebold lowers FY22 revenue view to $3.55B-$3.75B from $3.7B-$3.9B 08/02/22 Diebold reports Q2 non-GAAP EPS 38c, consensus (14c) 05/10/22 Diebold lowers FY22 revenue view to $3.7B-$3.9B from $4.0B-$4.2B 05/10/22 Diebold reports Q1 non-GAAP EPS ($1.61), consensus (21c) DBD Diebold $4.46 / -0.13 (-2.83%) 07/08/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Downgrade	Plexus downgraded to Underweight from Neutral at JPMorgan » 07:20 08/12/22 08/12 07:20 08/12/22 07:20 PLXS Plexus $95.69 / +0.88 (+0.93%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PLXS Plexus $95.69 / +0.88 (+0.93%) 08/08/22 Plexus opens manufacturing facility in Bangkok, Thailand PLXS Plexus $95.69 / +0.88 (+0.93%) 07/29/22 Needham Plexus price target raised to $105 from $93 at Needham 07/27/22 Benchmark Plexus initiated with a Buy at Benchmark 06/07/22 Raymond James Plexus upgraded to Outperform from Market Perform at Raymond James 01/28/22 Needham Plexus price target lowered to $90 from $95 at Needham PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Plexus sees Q4 GAAP EPS $1.19-$1.35, consensus $1.10 07/27/22 Plexus reports Q3 adjusted EPS $1.33, consensus $1.10 04/27/22 Plexus reports Q2 EPS 95c, consensus 99c 03/07/22 Plexus reaffirms Q2 EPS guidance 76c-92c, consensus 99c PLXS Plexus $95.69 / +0.88 (+0.93%) 07/27/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/24/22 Plexus
Downgrade	Cognex downgraded to Underweight from Neutral at JPMorgan » 07:19 08/12/22 08/12 07:19 08/12/22 07:19 CGNX Cognex $48.48 / +0.54 (+1.13%) JPMorgan analyst Paul… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly CGNX Cognex $48.48 / +0.54 (+1.13%) 06/09/22 Cognex discloses fire at primary manufacturing facility in Indonesia 03/03/22 Cognex authorizes up to $500M stock buyback program CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Needham Cognex price target lowered to $50 from $60 at Needham 08/03/22 Cowen Cognex price target lowered to $55 from $75 at Cowen 08/03/22 Stephens Cognex downgraded to Equal Weight at Stephens on logistics demand deteriorating 08/03/22 Stephens Cognex downgraded to Equal Weight from Overweight at Stephens CGNX Cognex $48.48 / +0.54 (+1.13%) 08/02/22 Cognex sees Q3 revenue $160M-$180M, consensus $290.25M 08/02/22 Cognex reports Q2 adjusted EPS 41c, consensus 41c 05/05/22 Cognex sees Q2 revenue $265M-$285M, consensus $292.72M 05/05/22 Cognex reports Q1 EPS 42c, consensus 38c CGNX Cognex $48.48 / +0.54 (+1.13%) 08/03/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/02/22 Fly Intel: After-Hours Movers 02/17/22 Fly Intel: After-Hours Movers
Recommendations	Six Flags price target lowered to $28 from $35 at Stifel » 07:18 08/12/22 08/12 07:18 08/12/22 07:18 SIX Six Flags $21.12 / -4.685 (-18.16%) Stifel analyst Steven… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags falls -22.5% 08/11/22 Six Flags falls -21.5% 08/11/22 Six Flags falls -18.1% 08/11/22 Six Flags reports Q2 attendance 6.7M vs. 8.5M a year ago, down 22% SIX Six Flags $21.12 / -4.685 (-18.16%) 05:44 Today KeyBanc Six Flags downgraded to Sector Weight at KeyBanc after 'indefensible' Q2 08/11/22 KeyBanc Six Flags downgraded to Sector Weight from Overweight at KeyBanc 07/08/22 Citi Six Flags downgraded to Neutral from Buy at Citi 06/24/22 Stifel Six Flags price target lowered to $35 from $52 at Stifel SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 Six Flags reports Q2 EPS 53c, consensus $1.02 08/10/22 Notable companies reporting before tomorrow's open 08/10/22 Notable companies reporting before tomorrow's open 05/12/22 Six Flags reports Q1 EPS (76c), consensus ($1.04) SIX Six Flags $21.12 / -4.685 (-18.16%) 08/11/22 What You Missed On Wall Street On Thursday 08/11/22 What You Missed On Wall Street This Morning 08/11/22 Fly Intel: Pre-market Movers 07/21/22 Fly Intel: After-Hours Movers
Hot Stocks	Unity Biotechnology announces anticipated milestones » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 UBX Unity Biotechnology / + UBX1325 24-week safety… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 07:17 Today Unity Biotechnology expects cash to fund operations through 1Q23 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	Toast price target raised to $25 from $18 at KeyBanc » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 TOST Toast $18.12 / -0.33 (-1.79%) KeyBanc analyst Josh Beck… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Options TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast up 9% to $19.80 after smaller than expected Q2 loss, raised guidance 07/26/22 Cathie Wood's ARK Investment bought 113K shares of Toast today 07/07/22 Toast acquires employee scheduling, communication solution Sling, no terms 05/13/22 Toast rises 15.2% TOST Toast $18.12 / -0.33 (-1.79%) 05/17/22 Mizuho Toast price target lowered to $18 from $19 at Mizuho 05/13/22 Needham Toast price target lowered to $21 from $38 at Needham 05/13/22 Canaccord Toast price target lowered to $25 from $34 at Canaccord 05/09/22 Mizuho Toast price target lowered to $19 from $23 at Mizuho TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast raises FY22 revenue view to $2.62B-$2.66B, consensus $2.54B 08/11/22 Toast sees Q3 revenue $700M-$730M, consensus $665.08M 08/11/22 Toast reports Q2 EPS (11c) vs (64c) last year 08/11/22 Notable companies reporting after market close 22 Sep TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Fly Intel: After-Hours Movers 05/13/22 What You Missed On Wall Street On Friday 05/13/22 What You Missed On Wall Street This Morning 05/13/22 Fly Intel: Pre-market Movers TOST Toast $18.12 / -0.33 (-1.79%) 08/11/22 Toast Inc options imply 11.3% move in share price post-earnings 05/12/22 Toast Inc options imply 21.6% move in share price post-earnings 03/04/22 Toast Inc put volume heavy and directionally bearish 02/15/22 Toast Inc options imply 15.0% move in share price post-earnings
Hot Stocks	PLx Pharma announces survey data on VAZALORE 81 mg » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 PLXP PLx Pharma $2.59 / +0.015 (+0.58%) PLx Pharma, with its lead… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 05/20/22 PLx Pharma showcases VAZALORE at SCAI annual meeting PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 03/15/22 BWS Financial BWS drops coverage of PLx Pharma, says off Amazon again 12/07/21 Raymond James Raymond James upgrades PLx Pharma on 'compelling entry point' 12/07/21 Raymond James PLx Pharma upgraded to Outperform from Market Perform at Raymond James 11/12/21 JMP Securities PLx Pharma reported strong quarter for Vazalore, says JMP Securities PLXP PLx Pharma $2.59 / +0.015 (+0.58%) 06:55 Today PLx Pharma reports Q2 EPS (52c), consensus (56c) 05/13/22 PLx Pharma reports Q1 non-GAAP EPS (66c), consensus (72c) 03/11/22 PLx Pharma reports Q4 adjusted EPS (73c), consensus (71c) 08:30 Today PLx Pharma - PLXP
Hot Stocks	Unity Biotechnology expects cash to fund operations through 1Q23 » 07:17 08/12/22 08/12 07:17 08/12/22 07:17 UBX Unity Biotechnology / + Cash, cash equivalents… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 04/28/22 Allogene Therapeutics appoints Lundeen as Chief People Officer UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 07:16 Today Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	Illumina price target lowered to $300 from $480 at Stifel » 07:16 08/12/22 08/12 07:16 08/12/22 07:16 ILMN Illumina $227.64 / +0.44 (+0.19%) Stifel analyst Daniel… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 core Illumina revenue growth view to 3.5%-4.5% 08/11/22 Illumina drops 22% to $177 after Q2 results miss estimates, FY22 guidance cut 06/09/22 Illumina drops 6% to $210.00 after departure of CFO 06/09/22 Illumina CFO Sam Samad to depart, Joydeep Goswami named interim CFO ILMN Illumina $227.64 / +0.44 (+0.19%) 06:59 Today Citi Illumina price target lowered to $200 from $220 at Citi 06:36 Today Baird Illumina price target lowered to $215 from $306 at Baird 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 07/14/22 Canaccord Illumina merger challenge not reflection of merits, says Canaccord ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina cuts FY22 adjusted EPS view to $2.75-$2.90 from $4.00-$4.20 08/11/22 Illumina reports Q2 adjusted EPS 57c, consensus 65c 08/11/22 Notable companies reporting after market close 05/05/22 Illumina sees FY22 adjusted EPS $4.00-$4.20, consensus $4.15 ILMN Illumina $227.64 / +0.44 (+0.19%) 07/27/22 Illumina's Grail deal likely to be blocked by EU regulators, Reuters reports 07/13/22 Illumina lost bid to block EU watchdog review of Grail deal, Bloomberg reports ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Fly Intel: After-Hours Movers 07/13/22 What You Missed On Wall Street On Wednesday 07/13/22 What You Missed On Wall Street This Morning 06/10/22 What You Missed On Wall Street On Friday 09/10/22 ESMO Congress 2022 ILMN Illumina $227.64 / +0.44 (+0.19%) 08/11/22 Illumina options imply 6.5% move in share price post-earnings 06/13/22 Illumina put buyer realizes 25% same-day gains 05/18/22 Early notable gainers among liquid option names on May 18th

Earnings	Unity Biotechnology reports Q2 EPS (19c) vs. (32c) last year » 07:16 08/12/22 08/12 07:16 08/12/22 07:16 UBX Unity Biotechnology / + Reports Q2 revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings UBX Unity Biotechnology / + 05/26/22 Unity Biotechnology appoints Michael Samar to board of directors 05/10/22 Unity Biotechnology announces upcoming milestones 05/05/22 Unity Biotechnology presents on UBX1325 at ARVO 2022 04/28/22 Allogene Therapeutics appoints Lundeen as Chief People Officer UBX Unity Biotechnology / + 05/17/22 Citi Unity Biotechnology price target lowered to $5 from $6 at Citi 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans 01/04/22 Roth Capital Unity Biotechnology upgraded to Buy from Neutral at Roth Capital 12/15/21 Wedbush Wedbush bullish on Unity Biotechnology, initiates with an Outperform UBX Unity Biotechnology / + 05/10/22 Unity Biotechnology reports Q1 EPS (28c), consensus (26c) 03/15/22 Unity Biotechnology reports Q4 EPS (18), consensus (38c)
Recommendations	CS Disco price target lowered to $30 from $40 at Stifel » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 LAW CS Disco $28.96 / +0.39 (+1.37%) Stifel analyst J. Parker… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly LAW CS Disco $28.96 / +0.39 (+1.37%) 06/06/22 DISCO appoints Tom Furr as CMO 06/01/22 CS Disco falls -10.8% 04/28/22 DISCO appoints Jignasha Amin Grooms as CHRO LAW CS Disco $28.96 / +0.39 (+1.37%) 06:15 Today BofA CS Disco downgraded to Neutral from Buy at BofA 06:05 Today Canaccord CS Disco downgraded to Hold from Buy at Canaccord 05:40 Today Cowen Cowen cuts CS Disco to Market Perform as momentum hits 'big snag' 05:35 Today Cowen CS Disco downgraded to Market Perform from Outperform at Cowen LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 CS Disco cuts FY22 revenue view to $132M-$136M from $149M-$153M 08/11/22 CS Disco sees Q3 revenue $32M-$34M, consensus $38.29M 08/11/22 CS Disco reports Q2 adjusted (23c), consensus (27c) 05/12/22 CS Disco sees Q2 revenue $32M-$34M, consensus $34.02M 15 Sep LAW CS Disco $28.96 / +0.39 (+1.37%) 08/11/22 Fly Intel: After-Hours Movers 05/12/22 Fly Intel: After-Hours Movers
Earnings	Real Good Food raises FY22 revenue $155M-$160M from $150M-$160M » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 RGF Real Good Food $6.93 / -0.11 (-1.56%) FY22 revenue consensus… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RGF Real Good Food $6.93 / -0.11 (-1.56%) 08/09/22 Real Good Food Company Inc trading resumes 08/09/22 Real Good Food Company Inc trading halted, volatility trading pause 07/06/22 Real Good Food launches Real Good Foods Perks Program 06/07/22 Real Good Food announces launch of chicken enchiladas in Sam's Club RGF Real Good Food $6.93 / -0.11 (-1.56%) 03/08/22 Roth Capital Real Good Food initiated with a Buy at Roth Capital 11/30/21 Fly Intel: Top five analyst initiations 11/30/21 Jefferies Jefferies starts Real Good Food at Buy, sees 75% upside in 12 months 11/30/21 Truist Real Good Food initiated with a Buy at Truist RGF Real Good Food $6.93 / -0.11 (-1.56%) 07:14 Today Real Good Food reports Q2 revenue $30.809M, consensus $32.12M 05/13/22 Real Good Food sees FY22 revenue $150M-$160M, consensus $143.65M 05/13/22 Real Good Food reports Q1 revenue $37.6M, consensus $32.47M 03/11/22 Real Good Food sees 2022 revenue $140M-$150M, consensus $120.57M 05 Nov 08:30 Today Real Good Food - RGF
General news	Market Update: » 07:15 08/12/22 08/12 07:15 08/12/22 07:15 $ECON Economic Data / + Market Update: Stock… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly $ECON Economic Data / + 06/22/22 President Biden calls on Congress to suspend federal gas tax 05/19/22 Could crypto crash be good for U.S. economy? Probably. 05/12/22 Miller calls out Taylor Morrison, GM as names that may work in this environment 04/21/22 Powell says 50 basis point hike on table for May meeting $ECON Economic Data / + $ECON Economic Data / + 06/14/22 Ackman says 100 point hike tomorrow 'would be better' than 75 $ECON Economic Data / + 07/26/22 Ackman says biggest risk to economy is inflation, not higher rates 06/17/22 White House, Congress in talks over bill to fight inflation, Bloomberg says 06/13/22 Fed more likely to consider 0.75 point hike given recent data, WSJ says 05/10/22 Tepper says covered Nasdaq short, CNBC reports $ECON Economic Data / + 07/27/22 What You Missed On Wall Street On Wednesday 07/21/22 What You Missed On Wall Street On Thursday 07/21/22 What You Missed On Wall Street This Morning 07/06/22 What You Missed On Wall Street On Wednesday
Earnings	Venus Concept sees 2022 revenue $110M-$113M, consensus $126.82M » 07:14 08/12/22 08/12 07:14 08/12/22 07:14 VERO Venus Concept / + The Company now expects… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events VERO Venus Concept / + 04/25/22 Venus Concept announces first patient treatment in study of Aime 03/31/22 Venus Concept submits FDA 510(k) for Aime robotic technology VERO Venus Concept / + 06/24/22 BTIG Venus Concept price target lowered to $5.50 from $7.00 at BTIG 11/12/21 Stifel Venus Concept price target trimmed to $2 at Stifel after Q3 miss VERO Venus Concept / + 07:14 Today Venus Concept reports Q2 EPS (16c), consensus (7c) 03/28/22 Venus Concept sees 2022 revenue $126M-$130M, consensus $125.9M 03/28/22 Venus Concept reports Q4 EPS (8c), consensus (10c) 09/29/22 7th Annual Healthcare Conference 08:00 Today Venus Concept - VERO

Events

Earnings calls, analyst events, roadshows and more

CMMB
Today at 08:00

Chemomab Therapeutics - CMMB Conference Calls
HUMA
Today at 08:00

Humacyte - HUMA Conference Calls
CAAS
Today at 08:00

China Automotive - CAAS Conference Calls
CASI
Today at 08:00

Casi Pharmaceuticals - CASI Conference Calls
GTEC
Today at 08:00

Greenland Technologies - GTEC Conference Calls
VERO
Today at 08:00

Venus Concept - VERO Conference Calls
EVK
Today at 08:00

Ever-Glory - EVK Conference Calls
Today at 08:30

Export Prices M/M: July 2022 Government Event
Today at 08:30

Export Prices Y/Y: July 2022 Government Event
Today at 08:30

Import Prices M/M: July 2022 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	AYTU X AYTU Aytu BioPharma Spot Secondary Managers: Cantor Fitzgerald & Canaccord Priced at: $0.43 21.5M Shares BRBR X BRBR BellRing Brands Spot Secondary Managers: JPMorgan, Barclays, Citi, Goldman Sachs & Morgan Stanley Priced at: $23.50 14.8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MDNA X MDNA Medicenna Therapeutics Spot Secondary Managers: Guggenheim, Bloom Burton Securities Priced at: $1.50 13.333M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial NUZE X NUZE NuZee Spot Secondary Managers: Maxim Priced at: $0.82 4.2M Shares PFLT X PFLT PennantPark Floating Rate Spot Secondary Managers: Morgan Stanley, Goldman Sachs, JPMorgan, Keefe Bruyette, RBC Capital & Truist Priced at: $12.40 4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	KRTX X KRTX Karuna Therapeutics Secondary Managers: Goldman Sachs & JPMorgan, Jefferies Priced at: $215.00 3.49M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial MIRM X MIRM Mirum Pharmaceuticals Spot Secondary Managers: JPMorgan, SVB Securities & Evercore ISI, Raymond James Priced at: $23.00 3.48M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TDW X TDW Tidewater Spot Secondary Managers: Morgan Stanley Priced at: $17.85 3.52M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	ATNX X ATNX Athenex Secondary Managers: SVB Securities Priced at: $.75 35.3M Shares CINC X CINC CinCor Pharma Secondary Managers: Goldman Sachs, Morgan Stanley, Jefferies & Piper Sandler Priced at: $30.00 7.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial EVTC X EVTC Evertec Secondary Managers: JPMorgan Priced at: $32.00 6.26M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LXU X LXU LSB Industries Secondary Managers: Goldman Sachs & UBS, Deutsche Bank, Jefferies, Piper Sandler, RBC Capital, BNP Paribas, Stifel Priced at: $13.00 13.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial SOVO X SOVO Sovos Brands Secondary Managers: JPMorgan & Goldman Sachs, BofA, Credit Suisse, Barclays, UBS, Cowen, Piper Sandler, Stifel, William Blair, Telsey Advisory, Drexel Hamilton, Loop Capital Priced at: $14.00 8.5M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VRNA X VRNA Verona Pharma Secondary Managers: Jefferies, Piper Sandler & Truist Priced at: $10.50 12.4M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial BNL X BNL Broadstone Net Lease Spot Secondary Managers: Goldman Sachs, BMO Capital, JPMorgan & Truist Priced at: $21.35 13M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial KIDS X KIDS OrthoPediatrics Spot Secondary Managers: Piper Sandler & Stifel Priced at: $55.00 750K Shares MAIN X MAIN Main Street Spot Secondary Managers: RBC Capital, UBS & Wells Fargo Priced at: $42.85 1.17M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	FRZA X FRZA Forza X1 IPO Managers: ThinkEquity Priced at: $5.00 3M Shares REBN X REBN Reborn Coffee IPO Managers: EF Hutton Priced at: $5.00 1.44M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TGL X TGL Treasure Global IPO Managers: EF Hutton Priced at: $4.00 2M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERE X CERE Cerevel Therapeutics Secondary Managers: Morgan Stanley, Goldman Sachs, Jefferies & Evercore ISI, Loop Capital, Seibert Williams Priced at: $35.00 7.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INAB X INAB In8bio Secondary Managers: H.C. Wainwright Priced at: $1.90 5.39M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial PTLO X PTLO Portillo's Secondary Managers: Jefferies & Morgan Stanley, BofA, Piper Sandler Priced at: $23.75 8M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial INSP X INSP Inspire Medical Spot Secondary Managers: Goldman Sachs Priced at: $215.00 1M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Fri	No deals

Mon	No deals
Tues	BIAF X BIAF Bioaffinity Technologies IPO Managers: WallachBeth $6.00-6.25 1.285M Shares
Wed	No deals
Thurs	RANI X RANI Rani Therapeutics Secondary Managers: BofA, Cantor Fitzgerald & UBS, BTIG, H.C. Wainwright $ Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial CERT X CERT Certara Spot Secondary Managers: Morgan Stanley $17.75-18.50 7M Shares
Fri	No deals

View All Syndicate Announcements »

Physicians Realty Trust downgraded to Underperform from Neutral at BofA

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access